 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | IMSA101 / ImmuneSensor Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov) - Dec 9, 2024
P2, N=16, Terminated, Sponsor: ImmuneSensor Therapeutics Inc.
N=51 --> 16 | Trial completion date: Feb 2026 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Nov 2024; Change in ImmuneSensor corporate strategy
- | IMSA101 / ImmuneSensor Therap
Phase classification, Trial completion date, Trial primary completion date, Metastases: A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov) - Nov 18, 2024
P1, N=2, Active, not recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
N=51 --> 16 | Trial completion date: Feb 2026 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Nov 2024; Change in ImmuneSensor corporate strategy Phase classification: P1/2 --> P1 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- || IMSA101 / ImmuneSensor Therap
Enrollment closed: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov) - Oct 9, 2024
P2, N=51, Active, not recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
Phase classification: P1/2 --> P1 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Recruiting --> Active, not recruiting
- | IMSA101 / ImmuneSensor Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC (clinicaltrials.gov) - Oct 9, 2024
P2, N=6, Terminated, Sponsor: ImmuneSensor Therapeutics Inc.
Recruiting --> Active, not recruiting N=46 --> 6 | Trial completion date: Feb 2026 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Sep 2024; Change in ImmuneSensor corporate strategy.
- | IMSA101 / ImmuneSensor Therap, Opdivo (nivolumab) / BMS
New P2 trial, Checkpoint inhibition: SPARK: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Sep 19, 2024
P2, N=20, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- | IMSA101 / ImmuneSensor Therap
Journal, CAR T-Cell Therapy: The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. (Pubmed Central) - May 11, 2024
Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion.
- IMSA101 / ImmuneSensor Therap
Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies. (Hall A; Poster Bd #: 156a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3084;
P2
OPD Study: 45 OPD solid tumor patients, randomized 1:2 to control arm vs. experimental arm (control: PULSAR + PD1 Ab, experimental arm: PULSAr + PD-1 Ab + IMSA 101). Primary endpoint: Progression-free rate at 12 months.
- IMSA101 / ImmuneSensor Therap
Enrollment closed, Metastases: A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov) - Oct 12, 2023
P1/2, N=2, Active, not recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
Primary endpoint: Progression-free rate at 12 months. Not yet recruiting --> Active, not recruiting
- ||| IMSA101 / ImmuneSensor Therap
Trial completion, Enrollment change, Trial completion date, Metastases: Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov) - Oct 11, 2023
P1/2, N=40, Completed, Sponsor: ImmuneSensor Therapeutics Inc.
Not yet recruiting --> Active, not recruiting Recruiting --> Completed | N=115 --> 40 | Trial completion date: Dec 2023 --> Sep 2023
- IMSA101 / ImmuneSensor Therap
Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_958;
Notable efficacy signals with both monotherapy and in combination with ICI were observed. Phase 2 randomized trials evaluating the combination of IMSA101, ICI and pulsed radiotherapy (PULSAR) in the settings of oligometastatic and oligo-progressive disease are now underway.
- IMSA101 / ImmuneSensor Therap
STING agonist-induced IL-18 secretion enhances CAR T cell function (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_680;
Conclusions In summary, we found that i. t. administration of IMSA101 promoted CART trafficking into the tumor, induced intratumoral CART activation, and enhanced CART efficacy, which was facilitated through STING agonist-mediated IL-18 induction. These promising observations laid the foundation for advancing the combinatorial approach into a clinic setting which is currently being planned.
- IMSA101 / ImmuneSensor Therap
New P1/2 trial, Metastases: A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov) - Sep 7, 2023
P1/2, N=2, Not yet recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
- ||| IMSA101 / ImmuneSensor Therap
Enrollment open: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov) - Aug 18, 2023
P2, N=51, Recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
These promising observations laid the foundation for advancing the combinatorial approach into a clinic setting which is currently being planned. Not yet recruiting --> Recruiting
- || IMSA101 / ImmuneSensor Therap
Enrollment open: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC (clinicaltrials.gov) - Jul 3, 2023
P2, N=46, Recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || IMSA101 / ImmuneSensor Therap
New P2 trial: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC (clinicaltrials.gov) - May 6, 2023
P2, N=46, Not yet recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
- |||| IMSA101 / ImmuneSensor Therap
New P2 trial: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov) - May 6, 2023
P2, N=51, Not yet recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
- IMSA101 / ImmuneSensor Therap
Combining CAR T Cell Therapy with Novel STING Agonist for Successful Treatment of Solid Tumors (Board No. 1271) - Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1919;
In summary, intratumoral administration of IMSA101 improved CART trafficking into the tumor, induced intratumoral CART activation, and significantly enhanced overall anti-tumor efficacy and overall survival in two syngeneic flank tumor models and in an immunodeficient model with human CART, suggesting direct and indirect mechanisms of enhanced antitumor immunity. These promising results paved the way for development of the combination approach into the clinic.
- || IMSA101 / ImmuneSensor Therap
Trial completion date, Trial primary completion date, Metastases: Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov) - Apr 19, 2023
P1/2, N=115, Recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
These promising results paved the way for development of the combination approach into the clinic. Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Oct 2023
- |||| IMSA101 / ImmuneSensor Therap
Dr. Zhijan Chen @UTSWNews presents his elegant work on the cGAS-cGAMP-STING pathway in host defense including anti-tumor innate immunity and autophagy #AACR21 cGAMP and stable analogue IMSA101 as therapeutics (Twitter) - Apr 11, 2021
- | IMSA101 / ImmuneSensor Therap
Enrollment open, Metastases: Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov) - Sep 25, 2019
P1/2, N=115, Recruiting, Sponsor: ImmuneSensor Therapeutics Inc.
Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Oct 2023 Not yet recruiting --> Recruiting
- | IMSA101 / ImmuneSensor Therap
New P1/2 trial, Metastases: Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov) - Jul 14, 2019
P1/2, N=115, Not yet recruiting, Sponsor: ImmuneSensor Therapeutics Inc.